A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

NCT06844214 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
32
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi